University at Buffalo - The State University of New York
Skip to Content
UBMD Physicians' Group

Clinical Trials

An Open-label Long-term Safety Study of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-23)

The study will be 28 weeks in duration.

The purpose of this study is to evaluate the study drug for efficacy (how well the drug works), safety (the side effects), and tolerability (how bearable) in children (7-11 years of age) and adolescents (12-17 years of age) with depression.

Eligibility

Participants must be between 7 and 17 years of age and have been depressed for at least 6 weeks.

Reimbursement

Yes

Investigator

PI: Steven Dubovsky, MD

Contact Information

Name: Sevie Kandefer, MS
Phone: (716) 898-4038
Email: sk293@buffalo.edu